Results

eNauka >  Rezultati >  A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
Naziv: A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
Autori: Unseld M.; Belic J.  ; Pierer K.; Zhou Q.; Moser T.; Bauer R.; Piringer G.; Gerger A.; Siebenhüner A.; Speicher M.;
Heitzer E.;
Godina: 2021
Publikacija: International Journal of Cancer
ISSN: 0020-7136 International Journal of Cancer Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 148 br. 6 str. 1452-1461
DOI : 10.1002/ijc.33303.
URI: https://www.cris.uns.ac.rs/record.jsf?recordId=131586&source=eNauka&language=en
https://enauka.gov.rs/handle/123456789/790539
M-kategorija: 
21aM21a - Vodeći međunarodni časopis kategorije M21a

Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.